LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Kodu・Aktsiate loetelu・Coherus Oncology Inc

Coherus Oncology Inc

Suletud

SektorTervishoid

1.74 -2.79

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.74

Max

1.8599999999999999

Põhinäitajad
By Trading Economics
Sissetulek	277M 241M
Müük	1.2M 13M
P/E Sektori keskmine	3.509 49.8
Kasumimarginaal	1,892.046
Töötajad	147
EBITDA	-2M -43M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+304.62% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	13M 259M
Eelmine avamishind	4.53
Eelmine sulgemishind	1.74

Uudiste sentiment

By Acuity

13%

87%

13 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

0.9209 / 1.05 Toetus ja vastupanu

Coherus Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. mai 2026, 23:41 UTC

Tulu

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6. mai 2026, 21:40 UTC

Tulu

Nutrien Logs Higher Profit, Sales Growth in 1Q

6. mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6. mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6. mai 2026, 23:13 UTC

Tulu

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6. mai 2026, 23:13 UTC

Tulu

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6. mai 2026, 23:12 UTC

Tulu

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6. mai 2026, 23:11 UTC

Tulu

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6. mai 2026, 23:07 UTC

Tulu

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6. mai 2026, 23:06 UTC

Tulu

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6. mai 2026, 23:06 UTC

Tulu

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6. mai 2026, 23:05 UTC

Tulu

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6. mai 2026, 23:04 UTC

Tulu

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6. mai 2026, 22:50 UTC

Tulu

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6. mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6. mai 2026, 22:11 UTC

Tulu

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6. mai 2026, 22:11 UTC

Tulu

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6. mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6. mai 2026, 21:58 UTC

Tulu

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. mai 2026, 21:47 UTC

Market Talk

Tulu

Costco Posts 13% Sales Growth in April -- Market Talk

6. mai 2026, 21:46 UTC

Tulu

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6. mai 2026, 21:40 UTC

Tulu

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6. mai 2026, 21:32 UTC

Kuumad aktsiad

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6. mai 2026, 21:29 UTC

Tulu

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Coherus Oncology Inc Prognoos

Hinnasiht

By TipRanks

304.62% tõus

12 kuu keskmine prognoos

Keskmine 7 USD 304.62%

Kõrge 10 USD

Madal 4 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Coherus Oncology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Coherus Oncology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9209 / 1.05Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

13 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.